since its formation in 1992, trinity biotech has actively pursued the aim of becoming a leading player in the international diagnostics industry. through a combination of sustained, organic growth and an acquisition-led strategy, the company has assembled an impressive product portfolio and achieved the highest standards of excellence in developing, manufacturing and marketing diagnostic products. the test kits manufactured by trinity biotech are used in the clinical laboratory and point-of-care segments of the diagnostic market to detect infectious diseases, sexually transmitted diseases, autoimmune and haemoglobin disorders, and detect, monitor and control diabetes. the company is also a significant provider of raw materials to the life sciences industry. trinity biotech, which has its headquarters in ireland, employs in excess of 350 people and markets its portfolio of over 400 products to customers in 80 countries around the world. it reaches this worldwide market by combining the
Company profile
Ticker
TRIB
Exchange
Website
CEO
Ronan O'Caoimh
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
TRIB stock data
Latest filings (excl ownership)
6-K
Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023
5 Apr 24
6-K
LifeSci Partners, LLC
16 Feb 24
6-K
LifeSci Partners, LLC
16 Feb 24
424B3
Prospectus supplement
15 Feb 24
6-K
LifeSci Partners, LLC
1 Feb 24
6-K
Trinity Biotech Announces Acquisition of the CGM Assets of
1 Feb 24
6-K
Trinity Biotech Announces It Has Begun Shipments of Its New
2 Jan 24
6-K
Trinity Biotech Announces Management Changes
19 Dec 23
6-K
Trinity Biotech Receives Non-Compliance Notice Regarding
29 Nov 23
6-K
Current report (foreign)
10 Oct 23
Latest ownership filings
SC 13D
PERCEPTIVE ADVISORS LLC
9 Feb 24
SC 13D/A
MiCo IVD Holdings, LLC
2 Jan 24
SC 13D/A
MiCo Co., Ltd.
2 Jan 24
SC 13G/A
STONEHILL CAPITAL MANAGEMENT LLC
13 Feb 23
SC 13G/A
RENAISSANCE TECHNOLOGIES LLC
13 Feb 23
SC 13D
MiCo IVD Holdings, LLC
8 Dec 22
SC 13G/A
RENAISSANCE TECHNOLOGIES LLC
11 Feb 22
SC 13G
STONEHILL CAPITAL MANAGEMENT LLC
4 Feb 22
SC 13G/A
Whitefort Capital Master Fund, LP
16 Feb 21
SC 13G/A
STONEHILL CAPITAL MANAGEMENT LLC
12 Feb 21
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 20 |
Opened positions | 3 |
Closed positions | 5 |
Increased positions | 1 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 752.08 mm |
Total shares | 52.88 mm |
Total puts | 100.00 |
Total calls | 4.30 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
MiCo IVD | 46.12 mm | $56.27 mm |
Hunter Associates Investment Management | 1.72 mm | $1.66 mm |
Stonehill Capital Management | 1.51 mm | $1.44 mm |
Renaissance Technologies | 1.37 mm | $1.31 mm |
Acadian Asset Management | 727.95 k | $701.00 k |
Whitefort Capital Master Fund | 585.57 k | $2.23 mm |
Whitefort Capital Management | 409.52 k | $389.49 mm |
Aristides Capital | 162.32 k | $154.38 mm |
Cambridge Investment Research Advisors | 111.40 k | $106.00 k |
MS Morgan Stanley | 38.23 k | $36.36 mm |
News
Trinity Biotech Says It Is Targeting Approximately $20M Of Annualized Run-rate EBITDA On Annualized Run-rate Revenues Of Approximately $75M By Q2, 2025
4 Apr 24
Trinity Biotech Q4 EPS $(0.72) Up From $(1.33) YoY, Sales $13.43M Miss $15.00M Estimate
4 Apr 24
Earnings Scheduled For April 4, 2024
4 Apr 24
Trinity Biotech Finalizes Effective Date As February 23, 2024 For ADS Ratio Change
15 Feb 24
12 Health Care Stocks Moving In Friday's After-Market Session
2 Feb 24
Press releases
Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financial Results & Business Updates
4 Apr 24
Trinity Biotech plc to Announce Q4 and Fiscal Year 2023 Financial Results
28 Mar 24
Trinity Biotech Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
8 Mar 24
Trinity Biotech Plc Finalizes Effective Date of ADS Ratio Change
15 Feb 24
Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change
13 Feb 24